Although several trials using anti-TNF-α blockers in patients with COPD have revealed no benefits, a large observational study reports reduced hospitalization rates in patients diagnosed with both COPD and rheumatoid arthritis (RA) and receiving TNF-α inhibitors [14]. This evidence concerns the gene TNF and rheumatoid arthritis.